O steoporosis is a common, chronic and costly condition affecting at least 25% of women and 12% of men over 50 years of age.
fractures; in that study, which involved 102 patients, the rate of treatment was 40% in the intervention group but only 10% in the group receiving usual care. 7 Several concerns were raised about the internal and external validity of that small study, so we conducted a randomized controlled trial of the intervention, which is reported here.
Methods

Setting and subjects
Capital Health (Edmonton, Alberta) is one of the largest integrated health delivery systems in Canada. There is uniform access to bone mineral density testing across the region, with average wait times of less than 1 week. We screened and recruited consecutive patients from the 2 largest emergency departments and the 2 largest fracture clinics in the region. Inclusion criteria were age 50 years or older and any distal forearm fracture, regardless of cause. Patients were excluded if they were already receiving treatment for osteoporosis with a bisphosphonate, were unable or unwilling to provide informed consent, had no fixed address, were residing outside the Capital Health region or were residing in a long-term care facility.
Study design and procedures
In this randomized controlled trial, patients were assigned to either the intervention group or the control group. Allocation was concealed by application of variable block sizes and by use of a secure, centralized, Internet-based, computer-generated randomization system housed within the Epidemiology Coordinating and Research Centre at the University of Alberta in Edmonton. Patients could not be blinded to the fact that they were part of an osteoporosis quality improvement study. However, physicians were not informed that their patients were part of a study, and neither physicians nor patients were aware of the study outcomes. Research nurses collected outcomes data without knowledge of allocation status. Investigators were blinded at all times. The University of Alberta Health Research Ethics Board approved the study.
Patients were approached in the emergency departments or while awaiting appointments in fracture clinics. After providing written informed consent, each study patient received a package that included instructions for cast care, information about the study and an Osteoporosis Canada pamphlet entitled "Osteoporosis: Are You at Risk?" The pamphlet described osteoporosis and its risk factors (highlighting the importance of fractures as a harbinger of future events), diagnosis and treatments; emphasized the importance of follow-up; and provided contact information (in the form of a toll-free number and a website address).
Protocol for control arm
We mailed another copy of the Osteoporosis Canada pamphlet to all patients in the control group, encouraging them to read it and discuss it with their respective primary care physicians. Physicians of control patients were routinely notified that their patients had been treated for a wrist fracture in the emergency department and were informed of follow-up plans and appointments.
Protocol for intervention arm
The overall purpose of the intervention was to deliver the following 3 messages to physicians (see Appendix 1, available at www.cmaj.ca/cgi/content/full/178/5/569/DC2/1) and patients (see Appendix 2, available at www.cmaj.ca/cgi/content/full/178 /5/569/DC2/2): (1) this patient is (you are) at high risk of osteoporosis, and a bone mineral density test is needed; (2) without treatment, this patient (you) may be at risk of a future fracture sooner rather than later (i.e., within 1 year); and (3) bisphosphonate treatment for fracture patients with low bone mass reduces the risk of future fracture by up to 50%. The third of these messages was qualified, however, by stating that bisphosphonates are not appropriate for all patients and that acceptable treatment alternatives include calcitonin (administered intranasally), hormone replacement therapy and raloxifene.
The intervention consisted of 3 components. First, we provided a brief counselling session to intervention patients by telephone, reiterating the same messages as the print materials (Appendix 2). This counselling was provided by an experienced registered nurse (D.B.) who had additional training and expertise in the diagnosis and treatment of osteoporosis. Beyond delivering the 3 study messages, the nurse answered questions and allayed concerns while emphasizing the importance of the patient communicating with his or her physician. The nurse did not interact directly with physicians. Second, we sent (by fax or mail) a patient-specific reminder to each physician of an intervention patient notifying the physician that his or her patient had recently received treatment for a wrist fracture and that the occurrence of the fracture indicated that the patient was at risk for osteoporosis. Third, evidence-based treatment guidelines, representing an actionable summary of available osteoporosis guidelines 1,2 and having endorsement from 5 local opinion leaders, were sent to these physicians. The local opinion leaders were nominated by regional primary care physicians who had received a previously validated sociometric questionnaire designed to identify educationally influential physician peers in the area of osteoporosis; 10, 11 further details are available upon request from the first author (S.R.M.). The reminder and the treatment guideline were designed to fit together on one printed page, were signed by the opinion leaders and were intended to become part of the patient's medical record (Appendix 1). In a formal microcosting study, we found that it took on average 10 minutes for an experienced nurse to complete all aspects of the intervention, and the cost was $9.64 per patient.
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Outcomes
The primary outcome was starting treatment with a bisphosphonate within 6 months after the fracture. This outcome was determined by patient self-report and was confirmed through dispensing records of local community pharmacies. There was 100% agreement between self-reporting and dispensing records. The main secondary outcomes were a bone mineral density test and a composite measure of quality that we referred to as guideline-concordant or "appropriate" care. Appropriate care was defined as having undergone a bone mineral density test and receiving bisphosphonate treatment if bone mass was low (i.e., a T score consistent with osteopenia [-1.0 to -2.5] or osteoporosis [-2.5 or worse] at any skeletal site). 1, 2, 13 This composite measure was justified because we anticipated that 30% of the patients would have normal bone mass and would thus be ineligible for bisphosphonate therapy.
1,2
Other measures
At baseline and 6 months, we used validated instruments to collect information regarding health status (with the Medical Outcomes Study Short Form-12 14 ), osteoporosis-related quality of life, 15 wrist-related functional outcomes (with the Upper Limb Disabilities of the Arm, Shoulder, and Hand instrument 16, 17 ), osteoporosis-related knowledge 18 and satisfaction with care.
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Sample size considerations
With bisphosphonate treatment at 6 months as the primary outcome, control treatment rates of no more than 10%, a 20% increase in treatment attributable to the intervention, α = 0.05 and β = 0.10, we calculated a minimum sample size of 184 patients (92 per arm) and then inflated this value by about one-half, to 272 patients.
Data analysis
The patient was the unit of allocation, analysis and causal inference. This was appropriate as we expected that few, if any, physicians would contribute more than 1 patient to the study. This assumption proved valid, as the 272 patients in the study were cared for by 266 different primary care physicians. In the main analysis, which was conducted according to the intention-to-treat principle, we compared the proportion of patients achieving the primary outcome in the intervention and control groups. A χ 2 test was used to determine statistical significance, and the strength of the association was described with relative risks (RRs) and 95% confidence intervals (CIs).
We prespecified that we would use multivariable logistic regression to adjust the analyses for any postrandomization baseline imbalances that were clinically important (i.e., > 10% difference between study arms) or statistically significant (i.e., p < 0.10). For continuous patient-reported outcomes, we used a similar analytic framework using t tests and multivariable linear regression. Because these were analyses of secondary outcomes, we examined only patients with complete information, rather than imputing any missing data.
Results
We screened 795 potentially eligible patients and excluded 523 ( Figure 1 ) and the rest from emergency departments. We randomly assigned 137 patients (with 135 different primary care physicians) to receive the intervention and 135 patients (131 physicians) to the control group. By study close-out at 6 months, 23 of the 272 patients (12 in the intervention group, 11 in the control group) had withdrawn from the study, had been lost to follow-up or had died (Figure 1 ).
Patient characteristics
The median age of the 272 study patients was 60 years (interquartile range 55-68 years), 210 (77%) were female, 130 (48%) reported a previous fracture after the age of 40 years, all reported a fall as the cause of their injury, and 71 (26%) reported a fall in the previous year. There were no significant differences between patients enrolled from the fracture clinics and those enrolled from the emergency departments. Intervention and control patients were comparable (Table 1) , although the intervention patients were somewhat more likely than controls to report acid peptic disease (p = 0.06), osteoarthritis (p = 0.03) and current smoking (p = 0.06), and they reported greater use of calcium (p = 0.04) and vitamin D (p = 0.06). All multivariable analyses presented hereafter were adjusted for these 5 variables. There were otherwise no significant differences between intervention and control patients.
Osteoporosis treatment
Six months after the fracture, 30 (22%) of the 137 intervention patients, as compared with 10 (7%) of the 135 controls, had achieved the primary study outcome of bisphosphonate treatment for osteoporosis (unadjusted RR 3.0; adjusted RR 2.6, 95% CI 1. No. included in analysis n = 135
No. included in analysis n = 137
Did not complete study
Did not complete study 
Bone mineral density testing
Within 6 months, 71 (52%) of the intervention patients, as compared with 24 (18%) of the control patients, had undergone a bone mineral density test (unadjusted RR 2.9; adjusted RR 2.8, 95% CI 1.9-4.2, p < 0.001) (Figure 2 ). Of the 95 patients who underwent bone mineral density testing, 27 (28%) had normal bone mass, 49 (52%) had osteopenia (T score -1.0 to -2.5), and 19 (20%) had osteoporosis (T score -2.5 or worse) at either the hip or the spine.
Appropriate care
Overall, 52 (38%) of the intervention patients, as compared with 15 (11%) of the control patients, received guidelineconcordant (appropriate) osteoporosis care (unadjusted RR 3.4; adjusted RR 3.1, 95% CI 1.8-5.3, p < 0.001) (Figure 2 
Other outcomes
Overall, by 6 months after randomization, 1 patient had died and 4 others had experienced recurrent clinical fracture. There were no statistically significant differences between intervention and control patients in patient-reported outcomes such as health status, upper extremity disability, osteoporosis-related quality of life or knowledge, or satisfaction with care (Table 2) .
Interpretation
In this randomized controlled trial with concealed allocation and blinded outcome ascertainment, involving 272 older patients with fracture of the wrist, we demonstrated that a multifaceted intervention led to improved rates of osteoporosis testing and treatment. Compared with an active control group, the intervention group had significantly greater rates of osteoporosis treatment (7% v. 22%) and bone mineral density testing (18% v. 52%) within 6 months after the fracture. All treated patients received a bisphosphonate, although intranasal calcitonin, hormone replacement therapy, raloxifene, and (currently) parathyroid hormone might be considered reasonable second-line alternatives. Overall, the intervention led to a 27% absolute increase in the delivery of guideline-concordant ("appropriate") care, which translates into a number needed to treat of 4 patients. Nevertheless, it should be acknowledged that more than half (62%) of the intervention patients were not receiving appropriate osteoporosis care within 6 months after their fracture, either because a bone mineral density test had not been done or because evidence of low bone mass had not been acted upon. This was a particular problem for men, who were about one-third as likely as women to receive appropriate care, irrespective of allocation status. Indeed, the rates of appropriate care for men in the intervention group (15%) were about the same as for women in the control group (14%), who in turn were more likely to receive appropriate care than men in the control group (3%). This disparity is most likely a result of the fact that both male patients 20 and their physi- cians 21 consider osteoporosis to be a condition that afflicts only elderly women, and our intervention (alone) was insufficient to overcome this profound attitudinal barrier.
Compared with our pilot study of the same intervention, the rates of osteoporosis treatment in the study reported here were lower: 22% of patients in the current study and 40% of those in the pilot study were being treated at 6 months after fracture. This difference could be related to bias (i.e., the pilot was stopped early), confounding (i.e., the pilot used nonrandom allocation) or chance. Alternatively, the estimate of effect for osteoporosis treatment in the pilot study (adjusted RR of 3.8) was within the 95% confidence interval of the effect found in this trial (1.3-5.1), which suggests equivalent benefit. Regardless, it is discouraging to note that, in the 2 years since our original study was published, there was no improvement in osteoporosis treatment rates with usual care after a fracture (10% in the pilot v. 7% in the current study) in our own health region. Similarly low rates of osteoporosis treatment after fracture have been reported elsewhere in Canada, in the United States, in Europe and in Australia.
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To our knowledge, there have been only 3 other randomized controlled trials of interventions to improve the quality of osteoporosis care for outpatients who have experienced a fracture, 22-24 and 2 of those interventions did not improve treatment.
22,23 Bliuc and associates 22 enrolled 159 patients from a single fracture clinic in Australia and randomly assigned them to active control (a letter noting risk factors and recommending follow-up by a primary care physician) or intervention (the same letter plus a free bone mineral density test). The intervention had no effect on osteoporosis treatment after 6 months (5% for intervention v. 7% for controls, p > 0.4).
Solomon and colleagues
23 enrolled 229 Blue Cross and Blue
Shield beneficiaries from New Jersey who had a previous fracture, randomly assigning them (as a subgroup in a much larger trial) to usual care or intervention (which consisted of academic detailing and reminders to physicians, and printed materials and automated telephone calls to patients). The intervention had no effect on osteoporosis treatment after 10 months (4% for intervention v. 1% for controls, p = 0.07).
The only other study with positive results was reported by Feldstein and colleagues, 24 who enrolled 311 older women from a health maintenance organization that was using computerized medical records and electronic prescribing. They randomly assigned them to usual care or interventions (1 or 2 patient-specific electronic reminders with locally developed guidelines for physicians, with or without mailing of printed materials to patients). After 6 months, the interventions were associated with greater rates of bone mineral density testing (49% for interventions v. 2% for controls, p < 0.001) and of osteoporosis treatment (28% v. 5%, p < 0.001). 24 Clearly, it is difficult to improve the quality of care for older patients with fractures, and the study by Feldstein and colleagues and our own studies demonstrate that many patients exposed to effective interventions remain untreated.
Like all 3 of the previous randomized trials, [22] [23] [24] we examined process-of-care measures and did not have adequate power to demonstrate reductions in harder outcomes such as recurrent fracture. However, process-of-care measures are more sensitive to changes in quality of care than harder outcomes such as mortality or clinical events and are widely recognized as acceptable and appropriate outcomes for qualityimprovement studies. planned ongoing follow-up of this study cohort. Third, we can only draw conclusions about the effect of the intervention package as a whole, not about any single component. Although some authorities might consider this a limitation, 27 an equal number might concur with us in suggesting that our intervention should simply be adopted as part of usual care and could serve as the active comparator control arm for future studies. We suggest that future studies be designed to better understand and explore all barriers to best practice and consider a variety of strategies. Such studies might examine the effects of repeated messaging and reminders to patients and physicians; investigate decision aids to better motivate patients, especially men; consider more clinically useful and directive bone mineral density reports; and, perhaps most important, consider the role of allied health professionals in acting as "fracture managers" to educate patients, facilitate bone mineral density testing and provide prescription treatments when appropriate.
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In conclusion, we found that a pragmatic and inexpensive multifaceted intervention directed at patients with fragility fractures and their primary care physicians improved rates of osteoporosis treatment and led to a tripling of the delivery of guideline-concordant (appropriate) care. Still, more than half of the patients in the intervention group did not receive appropriate care. We therefore need to find even more effective methods to translate what we already know into what we do everyday -with the caveat that any new interventions should be tested in controlled trials before widespread adoption. 
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